HSBC Holdings
DNA icon

HSBC Holdings’s Ginkgo Bioworks DNA Stock Holding History

HSBC Holdings’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,366
Closed -$31.4K – 3020
2024
Q2 		$31.4K Buy
2,366
+850
+56% +$25.4K ﹤0.01% 2853
2024
Q1 		$70.3K Sell
1,516
-127
-8% -$6.57K ﹤0.01% 2899
2023
Q4 		$110K Sell
1,643
-17
-1% -$1.04K ﹤0.01% 2588
2023
Q3 		$121K Buy
1,660
+347
+26% +$27.7K ﹤0.01% 2527
2023
Q2 		$99.8K Sell
1,313
-2,645
-67% -$157K ﹤0.01% 2428
2023
Q1 		$214K Buy
3,958
+1,356
+52% +$85.9K ﹤0.01% 2362
2022
Q4 		$171K Buy
2,602
+15
+0.6% +$1.38K ﹤0.01% 2809
2022
Q3 		$326K Buy
2,587
+1,224
+90% +$146K ﹤0.01% 2371
2022
Q2 		$132K Buy
1,363
+872
+178% +$106K ﹤0.01% 2985
2022
Q1 		$80K Hold
491
– – ﹤0.01% 3155
2021
Q4 		$168K Buy
+491
New +$233K ﹤0.01% 3070

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HSBC Holdings's DNA Position: Q3 2024 in Review

HSBC Holdings sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 2,366 shares — an estimated $31.4K sold.

HSBC Holdings first reported a position in DNA in Q4 2021 and held it in 11 quarters. The position peaked at $326K in Q3 2022. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • HSBC Holdings reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • HSBC Holdings sold 2,366 Ginkgo Bioworks shares in Q3 2024, an estimated $31.4K.
  • HSBC Holdings first reported a position in Ginkgo Bioworks in Q4 2021 and held it in 11 quarters.
  • HSBC Holdings's Ginkgo Bioworks position peaked at $326K in Q3 2022.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on HSBC Holdings's 13F filing for Q3 2024, filed 14 Nov 2024.